Simvastatin Sensitizes Radioresistant Prostate Cancer Cells by Compromising DNA Double-Strand Break Repair

• Egile Nagusiak: Yu-An Chen (Egilea), Hua-Wei Shih (Egilea), Yi-Chun Lin (Egilea), Hui-Ying Hsu (Egilea), Tsu-Fang Wu (Egilea), Chen-Han Tsai (Egilea), Chia-Lin Wu (Egilea), Hui-Yu Wu (Egilea), Jer-Tsong Hsieh (Egilea), Chih-Hsin Tang (Egilea), Chih-Ho Lai (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2018-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Prostate cancer (PCa) is one of the most prevalent male cancers in western world. Radiation therapy (RT) is commonly used to treat PCa patients. However, a certain proportion of patients develop radioresistant PCa cells, which results in metastatic disease. Statins, which inhibit 3-hydroxy-3-methyl...